Taken together, our results are consistent with the study of Salnikov et al. [46] in that EpCAM×CD3 potently stimulates pre-activated lymphocytes to secrete effector cytokines in the presence of EpCAM expressing tumor cells. Here, EPCAM is linked to neoplasm.